The FDA accepted a new drug application for Brimochol PF for the treatment of presbyopia and set a Prescription Drug User Fee ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

Axsome Therapeutics received a refusal-to-file letter from the Food and Drug Administration for its new drug application for its fibromyalgia drug AXS-14.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

David Fournier, Allison Glasunow, and Kourtney Mueller Merrill joined Sheppard, Mullin, Richter & Hampton as partners in its ...

Shares of Axsome Therapeutics, Inc. (AXSM) slumped 3% in the pre-market session on Monday after the company said that it has ...

Phathom Pharmaceuticals, Inc. secured FDA exclusivity for Voquezna in GERD until 2032, but slow uptake & financial issues ...

US FDA clears YolTech’s IND application for YOLT-101, an in vivo base editing therapy to treat heterozygous familial hypercholesterolemia: Shanghai, China Monday, June 9, 2025, ...

Investors reacted positively to the robust data, which PolyPid believes will accelerate global partnership discussions. The company also emphasized the absence of safety concerns raised by the ...

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 ...

President Donald Trump's new ban on travel to the United States by citizens from 12 mainly African and Middle Eastern ...

An experimental drug empowered by artificial intelligence to identify a novel therapeutic target for a severe lung disease ...